Congenital disorders
Mylab introduces MyNeoShield for newborn screening
Sep
Pune: Mylab Discovery Solutions announced a ground-breaking advancement in new-born screening (NBS) with the introduction of its patent-pending Point-of-Care Device named MyNeoShield for New-born Screening on Wednesday.
Newborn screening (NBS) is a critical public health program involving the testing of newborn infants for specific genetic, metabolic, and congenital disorders shortly after birth. Left undiagnosed and untreated, many children may develop mental retardation, learning disabilities, autism, dyslexia, behavioural abnormalities NBS can detect most preventable or treatable inherited metabolic disorders and genetic conditions, offering a rational and cost-effective approach to preventing these issues.
The Pune-based company claims that this device is set to transform the landscape of new-born healthcare by making screening faster, more accessible, and more affordable, ultimately saving lives and preventing lifelong illnesses. The device supports all the seven tests done for New-born screening globally.
The innovative device brings the power of new-born screening directly to healthcare providers, allowing for quick and efficient testing at the point of care, said the company in a statement. As per the company the three major reasons for it to be a game-changer are faster results, accessibility and its life saving impact.
Expressing enthusiasm on the development, Hasmukh Rawal, Co-founder & Managing Director of Mylab, said, “At Mylab, we are deeply committed to advancing healthcare through innovation and accessibility. Our Point-of-Care Device for New-born Screening is a testament to that commitment. By making screening faster and more accessible, we aim to save lives and ensure that every child has the opportunity for a healthy and promising future.”
This Point-of-Care Device for Newborn Screening is set to be available commercially from November. The company plans to take the device to global markets with its partners.
